Abstract
Many patients undergoing intravesical therapy for superficial bladder cancer will fail initial treatment; therefore additional bladder-sparing options are needed for these patients. The taxanes are potentially ideal agents for intravesical therapy as they have demonstrated efficacy as systemic agents and have little systemic absorption due to a large molecular weight. Early clinical research indicates minimal toxicities associated with the use of taxanes as an intravesical treatment. These agents may yet play an important role in the intravesical treatment of bladder cancer.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Kim SC, Steinberg GD. Medical management of patients with refractory carcinoma in situ of the bladder. Drugs Aging 18:335–344, 2001.
Malmström P-U, Wijkström, Lundholm C, et al. 5-year followup of a randomized prospective study comparing mitymycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. J Urol 161:1124–1127, 1999.
Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. Valrubicin Study Group. J Urol 163:761–767, 2000.
Palapattu GS, Haisfield-Wolfe ME, Walker JM, et al. Assessment of perioperative psychological distress in patients undergoing radical cystectomy for bladder cancer. J Urol 172:1814–1817, 2004.
Parkinson JP, Konety BR: Health related quality of life assessments for patients with bladder cancer. J Urol 172:2130–2136, 2004.
Babaian RJ, Smith DB. Effect of ileal conduit on patients' activities following radical cystectomy. Urology 37:33–35, 1991.
Crawford ED. Intravesical therapy for superficial cancer: need for more options. J Clin Oncol 20:3185–3186, 2002.
Bissey MC, Nohynek G, Sanderink GJ, et al. Docetaxel (Taxotere(R)): a review of preclinical and clinical experience. Part I: preclinical experience. AntiCancer Drugs 6:339–355; 363–8, 1995.
Hennequin C, Fiocanti N, Favaudon V. S-phase specificity of cell killing of docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer 71:1194–1198, 1995.
Rangel C, Niell H, Miller A, et al. Taxol and taxotere in bladder cancer: in vitro activity and urine stability. Cancer Chemother Pharmacol 33:460–464, 1994.
Roth BJ, Dreicer R, Einhorn LH et al. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12: 2264–70, 1994.
deWit R, Kruit WH, Stoter G, et al. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer 78:1342–1345, 1998.
Gitlitz BJ, Baker C, Chapman Y, et al. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 98:1863–1869, 2003.
Pectasides D, Glotsos J, Bountouroglou N, et al. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Ann Oncol 13:243–250, 2002.
Garcia del Muro X, Marcuello E, Guma J, et al. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer 86:326–330, 2002.
Pectasides D, Visvikis A, Aspropotamitis A, et al. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial. Eur J Cancer 36:74–79, 2000.
Uchio EM, Linehan WM, Figg WD, et al. A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder. J Urol 169:357–360, 2003.
Messing E, Catalona. Urothelial tumors of the urinary tract. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ (eds.) Campbell's Urology, 7rd Ed., vol. 3. PhiladelphiaP: WB Saunders Company, 2327–2410, 1998.
Song D, Wientjes MG, Au JL. Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol 40:285–292, 1997.
McKiernan JM, Masson P, Murphy AM, Goetzl M, Olsson CA, Petrylak DP, Desai M, Benson MC. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 24(19):3075–80, 2006.
Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H and Mason MD. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU International 93:485–90, 2004.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
McKiernan, J.M., Pierorazio, P.M. (2009). Beyond BCG: Taxanes. In: Lee, C., Wood, D. (eds) Bladder Cancer. Current Clinical Urology. Humana Press. https://doi.org/10.1007/978-1-59745-417-9_13
Download citation
DOI: https://doi.org/10.1007/978-1-59745-417-9_13
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-58829-988-8
Online ISBN: 978-1-59745-417-9
eBook Packages: MedicineMedicine (R0)